Max Peters

2.7k total citations · 1 hit paper
76 papers, 1.5k citations indexed

About

Max Peters is a scholar working on Pulmonary and Respiratory Medicine, Radiation and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Max Peters has authored 76 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Pulmonary and Respiratory Medicine, 22 papers in Radiation and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Max Peters's work include Prostate Cancer Diagnosis and Treatment (43 papers), Prostate Cancer Treatment and Research (40 papers) and Advanced Radiotherapy Techniques (22 papers). Max Peters is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (43 papers), Prostate Cancer Treatment and Research (40 papers) and Advanced Radiotherapy Techniques (22 papers). Max Peters collaborates with scholars based in Netherlands, United Kingdom and Germany. Max Peters's co-authors include Olle ten Cate, Marinus A. Moerland, Jochem R.N. van der Voort van Zyp, Marco van Vulpen, Hashim U. Ahmed, Peter S.N. van Rossum, Manit Arya, Richard Hindley, Taimur T. Shah and Mathias Winkler and has published in prestigious journals such as PLoS ONE, The Journal of Urology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Max Peters

71 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer

2018 225 citations Stephanie Guillaumier, Max Peters et al. European Urology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Max Peters Netherlands	20	980	362	290	263	230	76	1.5k
Sabine Bieri Switzerland	24	570 0.6×	295 0.8×	585 2.0×	262 1.0×	118 0.5×	53	1.6k
Thomas P. Shakespeare Australia	19	690 0.7×	347 1.0×	286 1.0×	291 1.1×	112 0.5×	85	1.3k
Graeme Duncan Canada	19	1.8k 1.9×	661 1.8×	298 1.0×	242 0.9×	135 0.6×	35	2.1k
Per Fransson Sweden	19	1.8k 1.9×	672 1.9×	423 1.5×	366 1.4×	157 0.7×	80	2.4k
Erik C. Schimmel Netherlands	11	759 0.8×	456 1.3×	235 0.8×	167 0.6×	80 0.3×	18	1.3k
Charles Hayter Canada	24	932 1.0×	505 1.4×	568 2.0×	325 1.2×	64 0.3×	56	2.0k
Peter F. Orio United States	22	1.2k 1.2×	513 1.4×	254 0.9×	239 0.9×	135 0.6×	138	1.6k
Caro C.E. Koning Netherlands	24	610 0.6×	236 0.7×	255 0.9×	201 0.8×	50 0.2×	50	2.2k
Xiangmei Gu United States	20	567 0.6×	104 0.3×	352 1.2×	110 0.4×	106 0.5×	63	1.1k
Vedang Murthy India	29	1.6k 1.6×	842 2.3×	1.2k 4.0×	666 2.5×	126 0.5×	182	3.3k

Countries citing papers authored by Max Peters

Since Specialization

Citations

This map shows the geographic impact of Max Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Peters more than expected).

Fields of papers citing papers by Max Peters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Peters. The network helps show where Max Peters may publish in the future.

Co-authorship network of co-authors of Max Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Max Peters. A scholar is included among the top collaborators of Max Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Peters. Max Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peters, Max, Marieke van Son, Marinus A. Moerland, et al.. (2023). Recurrence characteristics after focal salvage HDR brachytherapy in prostate cancer. Radiotherapy and Oncology. 180. 109495–109495. 5 indexed citations

Chin, Joseph L., et al.. (2023). A Canadian center’s experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities. Canadian Urological Association Journal. 17(12). 1 indexed citations

Peters, Max, P.H.J. Kurver, Todd Manning, et al.. (2022). Nomogram predicting the probability of spontaneous stone passage in patients presenting with acute ureteric colic. British Journal of Urology. 130(6). 823–831. 6 indexed citations

Son, Marieke van, Marinus A. Moerland, Bart de Keizer, et al.. (2022). Value of Targeted Biopsies and Combined PSMA PET/CT and mp-MRI Imaging in Locally Recurrent Prostate Cancer after Primary Radiotherapy. Cancers. 14(3). 781–781. 12 indexed citations

Zweemer, Ronald P., Trudy N. Jonges, Femke van der Leij, et al.. (2022). Prognostic impact of waiting time between diagnosis and treatment in patients with cervical cancer: A nationwide population-based study. Gynecologic Oncology. 165(2). 339–346. 3 indexed citations

Werensteijn-Honingh, Anita M., Max Peters, P.S. Kroon, et al.. (2021). Progression-free survival in patients with ⁶⁸Ga-PSMA-PET-directed SBRT for lymph node oligometastases. Acta Oncologica. 60(10). 1342–1351. 7 indexed citations

Moerland, Marinus A., Leonard J. van Schelven, Max Peters, et al.. (2021). MR compatibility, safety and accuracy of the redesigned UMC Utrecht single needle implant device. Physics in Medicine and Biology. 66(12). 12NT02–12NT02. 1 indexed citations

Peters, Max, Anne S. R. van Lindert, Linda M. de Heer, et al.. (2021). Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival?. Annals of Surgical Oncology. 29(3). 1807–1814. 1 indexed citations

Lovegrove, Catherine, Max Peters, Stephanie Guillaumier, et al.. (2020). Evaluation of functional outcomes after a second focal high‐intensity focused ultrasonography (HIFU) procedure in men with primary localized, non‐metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. British Journal of Urology. 125(6). 853–860. 26 indexed citations

10.

Son, Marieke van, Evelyn M. Monninkhof, Max Peters, J J W Lagendijk, & Jochem van der Voort van Zyp. (2020). Health-related quality of life after ultrafocal salvage high-dose-rate brachytherapy for radiorecurrent prostate cancer: reporting the patient’s perspective. Clinical and Translational Radiation Oncology. 25. 81–87. 1 indexed citations

11.

Ven, Saskia van de, H.J.G.D. van den Bongard, N. Kasperts, et al.. (2020). Patient-Reported Outcomes of Oligometastatic Patients After Conventional or Stereotactic Radiation Therapy to Bone Metastases: An Analysis of the PRESENT Cohort. International Journal of Radiation Oncology*Biology*Physics. 107(1). 39–47. 21 indexed citations

12.

Peters, Max, Marieke van Son, Marinus A. Moerland, et al.. (2019). MRI-Guided Ultrafocal HDR Brachytherapy for Localized Prostate Cancer: Median 4-Year Results of a feasibility study. International Journal of Radiation Oncology*Biology*Physics. 104(5). 1045–1053. 27 indexed citations

13.

Guillaumier, Stephanie, Max Peters, Manit Arya, et al.. (2018). A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. European Urology. 74(4). 422–429. 225 indexed citations breakdown →

14.

Peters, Max, et al.. (2017). An easy‐to‐use scoring index to determine severity of mitral regurgitation by 2D echocardiography in clinical practice. Echocardiography. 34(9). 1275–1283. 4 indexed citations

15.

Janssens, Geert O., Lorenza Gandola, Stéphanie Bolle, et al.. (2017). Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. European Journal of Cancer. 73. 38–47. 89 indexed citations

16.

Peters, Max, Jochem R.N. van der Voort van Zyp, Marinus A. Moerland, et al.. (2016). Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer. Brachytherapy. 15(3). 296–305. 15 indexed citations

17.

Shah, Taimur T., Max Peters, Abi Kanthabalan, et al.. (2016). PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure. Prostate Cancer and Prostatic Diseases. 19(3). 311–316. 14 indexed citations

18.

Peters, Max, Jochem van der Voort van Zyp, C.J.M. Hoekstra, et al.. (2015). Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints. Radiotherapy and Oncology. 117(2). 262–269. 10 indexed citations

19.

Peters, Max, C.J.M. Hoekstra, Jochem R.N. van der Voort van Zyp, et al.. (2015). Rectal dose constraints for salvage iodine-125 prostate brachytherapy. Brachytherapy. 15(1). 85–93. 11 indexed citations

20.

Peters, Max. (1962). Going places with mathematics. Prentice Hall eBooks.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact